

# Influenza Vaccine Products for the 2025–2026 Influenza Season

| Manufacturer | Trade Name<br>(vaccine abbreviation) <sup>1</sup> | How Supplied                          | Mercury<br>Content<br>(mcg Hg/0.5mL) | Age Range                        | CVX<br>Code | Vaccine Product<br>Billing Code <sup>2</sup> |
|--------------|---|---------------------------------------|--------------------------------------|----------------------------------|-------------|--|
|              |   |                                       |                                      |                                  |             | CPT  |
| AstraZeneca  | FluMist (LAIV3)                                   | 0.2 mL (single-use nasal spray)       | 0                                    | 2 through 49 years               | 111         | 90660  |
|              |   |                                       |                                      |                                  | 333*        | NA*  |
| GSK          | Fluarix (IIV3)                                    | 0.5 mL (single-dose syringe)          | 0                                    | 6 months & older <sup>3</sup>    | 140         | 90656  |
|              | FluLaval (IIV3)                                   | 0.5 mL (single-dose syringe)          | 0                                    | 6 months & older <sup>3</sup>    | 140         | 90656  |
| Sanofi       | Flublok (RIV3)                                    | 0.5 mL (single-dose syringe)          | 0                                    | 9 years & older                  | 155         | 90673  |
|              | Fluzone (IIV3)                                    | 0.5 mL (single-dose syringe)          | 0                                    | 6 months & older <sup>3</sup>    | 140         | 90656  |
|              |   | 0.5 mL (single-dose vial)             | 0                                    | 6 months & older <sup>3</sup>    | 140         | 90656  |
|              |   | 5.0 mL multi-dose vial (0.25 mL dose) | 25 <sup>4</sup>                      | 6 through 35 months <sup>3</sup> | 141         | 90657  |
|              |   | 5.0 mL multi-dose vial (0.5 mL dose)  | 25 <sup>4</sup>                      | 6 months & older                 | 141         | 90658  |
|              | Fluzone High-Dose (HD-IIV3)                       | 0.5 mL (single-dose syringe)          | 0                                    | 65 years & older <sup>5</sup>    | 135         | 90662  |
| CSL Seqirus  | Afluria (IIV3)                                    | 5.0 mL multi-dose vial (0.25 mL dose) | 24.5 <sup>4</sup>                    | 6 through 35 months <sup>3</sup> | 141         | 90657  |
|              |   | 5.0 mL multi-dose vial (0.5 mL dose)  | 24.5 <sup>4</sup>                    | 3 years & older <sup>6</sup>     | 141         | 90658  |
|              |   | 0.5 mL (single-dose syringe)          | 0                                    | 3 years & older <sup>3</sup>     | 140         | 90656  |
|              | Fluad (aIIV3)                                     | 0.5 mL (single-dose syringe)          | 0                                    | 65 years & older <sup>5</sup>    | 168         | 90653  |
|              | Flucelvax (ccIIV3)                                | 0.5 mL (single-dose syringe)          | 0                                    | 6 months & older <sup>3</sup>    | 153         | 90661  |
|              |   | 5.0 mL multi-dose vial (0.5 mL dose)  | 25 <sup>4</sup>                      | 6 months & older <sup>3</sup>    | 320         | 90661  |

## NOTES

1. All 2025–2026 seasonal influenza vaccines are trivalent. IIV = egg-based inactivated influenza vaccine (injectable); where necessary to refer to cell culture-based vaccine, the prefix “cc” is used (e.g., ccIIV); RIV = recombinant hemagglutinin influenza vaccine (injectable); aIIV = adjuvanted inactivated influenza vaccine.

2. An administration code should always be reported in addition to the vaccine product code. Note: Third party payers may have specific policies and guidelines that might require providing additional information on their claim forms.

3. Dosing for infants and children age 6 through 35 months:

- Afluria 0.25 mL
- Fluarix 0.5 mL
- Flucelvax 0.5 mL
- FluLaval 0.5 mL
- Fluzone 0.25 mL or 0.5 mL

4. In June 2025, ACIP voted to no longer recommend use of inactivated influenza multi-dose vials (MDV) containing thimerosal as a preservative. Availability of MDV formulations varies by manufacturer. As of August 4, 2025, CDC's website states that there is no evidence of harm caused by the low doses of thimerosal in vaccines, except for minor reactions like redness and swelling at the injection site.

5. Solid organ transplant recipients age 18 through 64 years who are on immunosuppression medication regimens may receive either high-dose IIV (HD-IIV) or adjuvanted IIV (aIIV) influenza vaccine as options for influenza vaccination, without a preference over other age-appropriate IIVs or RIVs.

6. Afluria is approved by the Food and Drug Administration for intramuscular administration with the PharmaJet Stratis Needle-Free Injection System for persons age 18 through 64 years.

\* Self- or caregiver-administered at home

